Abstract 237P
Background
The purpose of this paper is to report the dosimetric effects of conscious sparing of contralateral lobe of thyroid gland in select head and neck patients receiving intensity-modulated radiotherapy to ipsilateral neck only. In unilaterally treated neck, the thyroid lobe present contralaterally is passively spared. We compared the effects of consciously sparing it and associated dosimetric results and their statistical significance.
Methods
Treatment plans of 38 buccal mucosa cancer patients, treated to ipsilateral side only, receiving same dose and fractionation to buccal mucosa & elective neck irradiation were evaluated. Since October 2021 we adopted a department protocol of conscious sparing of contralateral thyroid in unilaterally treated head and neck cancer patients. 19 of these had conscious sparing of contralateral thyroid (group A) whereas 19 of old plans were evaluated when C/L thyroid were not given constraints & are being passively spared due to location on contralateral/non treatment side of neck (group B). Treatment planning was done using 7 beam (6 MV) IMRT in Eclipse 13.7 TPS in all of these patients. The best treatment plans were selected ensuring 95% PTV dose coverage and acceptable dose to organs at risk (OARs). Uniform contouring, plan optimization and evaluation protocols were followed for all of these patients.
Results
The mean dose of thyroid in group A was 10.23Gy whereas in group B it was 19.35Gy which is statistically significant (P value – 0.0001). The mean thyroid volume in group A was 4.76cc and in group B was 5.86cc which is not significant statistically different from group B, thyroid dose. Table: 237P
Groups | No. | Mean ± SD | ‘t’ value | P value |
Thyroid dose with constraint | 19 | 10.23 ± 2.18 | 9.004, df=36 | 0.0001* |
Thyroid dose without constraint | 19 | 19.35 ± 3.84 |
Unpaired ‘t’ test applied. P value = 0.0001, Significant
Conclusions
Unilateral treatment of neck passively reduces dose to OARs present on the contralateral side. This study emphasizes that conscious sparing of contralateral thyroid lobe can further reduce the dose to significant levels. This reduction can preserve thyroid function further. Larger clinical trials are required to corroborate this dosimetric gain with clinical thyroid function preservation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
214P - Versican G3 domain promotes myeloma cell proliferation, migration and invasion via activation of FAK/STAT3 signaling
Presenter: Nidhi Gupta
Session: Poster viewing 03
215P - Prospective observational study to evaluate impact of metabolic tumor volume on baseline 18F FDG PET/CT and molecular markers on tumor response rate in patients with diffuse large B-cell lymphoma
Presenter: Ankur Mudgal
Session: Poster viewing 03
216P - Lenalidomide maintenance after whole brain radiotherapy in relapsed/refractory primary CNS lymphoma
Presenter: Bhausaheb Bagal
Session: Poster viewing 03
217P - Role of copper levels in patients with myelodysplastic syndromes
Presenter: Revanth Boddu
Session: Poster viewing 03
218P - Prognostic role of apoptotic index in acute lymphoblastic leukemia
Presenter: Ramya Ramesh
Session: Poster viewing 03
219TiP - Randomised controlled study to compare efficacy & safety of KRd versus VRd regimens in newly diagnosed multiple myeloma using weekly schedule of generic carfilzomib
Presenter: Jasmine Porwal
Session: Poster viewing 03
233P - Cancer awareness, tobacco use and cessation among Malayali tribes, Yelagiri Hills, Tamil Nadu, India: A 8-year follow up study
Presenter: Delfin Lovelina Francis
Session: Poster viewing 03
234P - Epithelial-mesenchymal transition and cancer stem cells: Missing link in oral squamous cell carcinoma
Presenter: Selvaraj Jayaraman
Session: Poster viewing 03
235P - Evaluation of a prognostic model for head and neck cutaneous squamous cell carcinoma using a cumulative number of risk factors
Presenter: Reiichi Doi
Session: Poster viewing 03